Global Conference 2014

Staring down the barrel of a cancer diagnosis usually means enduring the harsh side effects of chemotherapy. Could the end of chemotherapy be near? Researchers have made great strides toward replacing these treatments with our natural defense mechanism - the immune system. Immunotherapy pioneers have figured out how to teach our immune cells to recognize and mobilize against cancer cells like snipers, thus moving away from the chemo-bombs that can't distinguish malignant cells from healthy ones. Immunotherapy may very well be the anti-cancer silver bullet, and pharma companies and investors are lining up to place big bets on the new weapon. This panel will discuss how the oncology community is harnessing immunotherapy and how researchers are optimizing their methods to get closer to a cure.


Jonathan Simons

President and CEO, Prostate Cancer Foundation; Senior Advisor, Milken Institute


Charles Drake

Associate Professor of Oncology, Immunology and Urology, Johns Hopkins University and James Buchanan Brady Urological Institute

Padmanee Sharma

Associate Professor, Genitourinary Medical Oncology and Immunology, and Scientific Director, Immunotherapy Platform, University of Texas MD Anderson Cancer Center

Elliott Sigal

Board Member, Melanoma Research Alliance; Former Chief Scientific Officer, Bristol-Myers Squibb

Jedd Wolchok

Chief, Melanoma and Immunotherapeutics Service, and Lloyd J. Old and Virginia and Daniel K. Ludwig Chair for Clinical Investigation, Memorial Sloan Kettering Cancer Center

Return to Program Detail